Navigation Links
CVS Caremark Insights 2011 Report Highlights Lowest Drug Trend in Six Years and Increased Utilization of Generics
Date:4/14/2011

WOONSOCKET, R.I., April 14, 2011 /PRNewswire/ -- CVS Caremark (NYSE: CVS) today released its annual Insights Report, which reviews drug trend and highlights key areas to watch in pharmacy care.  In 2010, the average drug trend for the company's pharmacy benefit management (PBM) client segments -- employers, health plans and third party administrators -- was 2.4 percent, the lowest trend in six years, demonstrating that CVS Caremark helped its clients and their members effectively manage pharmacy costs during a tough economic year.

(Logo: http://photos.prnewswire.com/prnh/20090226/NE75914LOGO)

"Last year was one of uncertainty and change for our clients as they worked to understand the impact of health care reform while also dealing with a sluggish economic recovery," said Per Lofberg, president of CVS Caremark's pharmacy benefit management business.  "One of our priorities is to help our clients navigate health care reform and determine how best to implement necessary changes.  Even with this added layer of complexity, we helped our clients manage costs and maintain quality care for their members."

The company's 2010 drug trend was held in check by the increasing use of generics as more of these less expensive medications became available, more physicians prescribed them and more members were willing to use generics. The company's generic dispensing rate (GDR) was 71.5 percent.  Other trend drivers included continued growth in the utilization of complex specialty pharmaceuticals, as well as an increase in utilization of prescription drugs overall.  CVS Caremark anticipates these trends will continue this year and, when coupled with the growing impact of chronic disease, sees a need to integrate and coordinate pharmacy care in a centralized location -- a pharmacy home -- to  help members coordinate and simplify  their medication
'/>"/>

SOURCE CVS Caremark
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CVS Caremark Named One of Americas Most Reputable Companies by Reputation Institute
2. CVS Caremark Research Finds "Dispense as Written" Prescriptions May Add $7.7 Billion to Annual Health Care Costs
3. CVS Caremark Charitable Trust Makes Initial Donation of $100,000 to Relief Effort in Japan
4. CVS Caremark Announces Agreement With ActiveHealth Management for Evidence-Based Clinical Decision Support
5. CVS Caremark and Universal American Announce Termination of Hart-Scott-Rodino Waiting Period
6. CVS Caremark Awarded Pharmacy Benefit Management Institute Rx Benefit Innovation Award for Pharmacy Advisor Program
7. CVS Caremark Corporation to Hold Fourth Quarter 2010 Conference Call
8. CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions
9. CVS Caremark Announces Interim Leadership for Retail Business
10. CVS Caremark Study Finds Patients with Complex Therapies Struggle to Stay Adherent to their Medications
11. CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... La Mirada, CA (PRWEB) , ... June 29, ... ... organizations, has announced that Dr. Gabriel Martin Del Campo is their newest FAA-certified ... Administration (FAA) physical examination is available for all fledging pilots seeking to obtain ...
(Date:6/29/2015)... ... June 29, 2015 , ... The Society for Immunotherapy ... (EMA) has granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment ... the approval of nivolumab for patients with metastatic melanoma in Europe represents a ...
(Date:6/29/2015)... ... ... Displays and Exhibits , a top online retailer of trade ... that include branding. Enter price code brand2015 for a ten percent discount on all ... promotional materials, all should integrate the company logo to communicate the brand. What is ...
(Date:6/29/2015)... ... 29, 2015 , ... Brittenford Systems, a provider of financial ... businesses across the United States, has announced that it has been named to ... year. , Based on company revenue and number of employees, Bob Scott’s Top ...
(Date:6/29/2015)... ... June 29, 2015 , ... Human Factors and Usability ... 16, 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/humanfactors , ... engineering to the design of new products as well as to postmarket surveillance ...
Breaking Medicine News(10 mins):Health News:Healthpointe Now Offering FAA Physical Exams in San Bernardino County 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3Health News:Stock Up on Logo Branding Tools Reduced this Month and Next Month from Displays and Exhibits 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3
... focused new and improved interface. The most highlighting feature of this ... consumers to choose and buy their niche medicines any time. ... ... most reliable online pharmacy, launched a brand new customer focused, well ...
... for Two to International DestinationsSALT LAKE CITY, April 5 ... destination -- by winning it, with the launch of their ... Advanced." Schiff(R) will award seven grand prize winners a ... eight international destinations as well as 10,000 secondary prizes of ...
... 4 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the ... that it will attend the upcoming Goldman Sachs Leveraged ... 8, 2009 at the Goldman Sachs Conference Center located ...
... maker of lubricious HYDAK® hydrophilic coatings, and Agion Technologies, the ... co-marketing agreement to develop and promote a coatings product line ... ... Horsham, PA (PRWEB) April 4, 2009 -- ...
... Inc. (Nasdaq: BNVI ), a leader in the ... areas of women,s health and cancer, is scheduled to present ... City on April 9, 2009 at 3:45 p.m. MST.Mary Tagliaferri, ... The purpose of the presentation will be to update investors ...
... Departments Urge Public to Self-Report Suspected MeaslesHARRISBURG, Pa., April 3 ... Allegheny County Health Department and UPMC,s Children,s Hospital of Pittsburgh ... seen at Children,s Hospital. Exposures to measles may have occurred ... , ...
Cached Medicine News:Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 2Health News:Rxonlinetoday Launch Cyber Shop for FDA Approved Medicines 3Health News:Schiff Announces New 'Trip of a Lifetime' Sweepstakes 2Health News:Schiff Announces New 'Trip of a Lifetime' Sweepstakes 3Health News:Biocoat and Agion to Develop and Co-market Coatings for Medical Devices. 2Health News:Biocoat and Agion to Develop and Co-market Coatings for Medical Devices. 3Health News:Bionovo to Present at the Cambria Capital Investor Meeting 2Health News:Bionovo to Present at the Cambria Capital Investor Meeting 3Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 2Health News:Pennsylvania State Department of Health and Allegheny County Health Department Confirm Four Cases of Measles in Southwest Region 3
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: